GLOBAL LIVER INSTITUTE
Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most common liver disease in the world – nonalcoholic fatty liver disease (NAFLD) – and it’s more severe form, nonalcoholic steatohepatitis (NASH).
Despite acknowledging OCA met the endpoint established by the FDA of reducing fibrosis by at least one stage, GIDAC voted against approval for treatment for NASH.
On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic Acid (OCA) for Non-Alcoholic Steatohepatitis: Effectiveness and Value. While the evidence presented for both drugs was deemed effective in fibrosis regression, ICER inconsistently voted to show that there was only a net health benefit in favor of resmetirom, being superior to lifestyle management alone, and not in OCA.
Today, the Institute for Clinical and Economic Review (ICER) will hold a public hearing on its draft assessment of Resmetirom and Obeticholic Acid for Non-Alcoholic Steatohepatitis: Effectiveness and Value.
The members of the Liver Action Network (LAN) pledge collective support for Living Donor Day to honor the donors, recipients, families and caregivers, and clinical teams that make the lifesaving gift of organ donation possible.
Global Liver Institute commends Health Resources and Services Administration (HRSA)’s recent announcement that it will break up the Organ Procurement and Transplantation Network (OPTN) monopoly.
GLI CEO Donna R. Cryer addresses the concerns of the liver disease community about the senseless rising incidence of liver disease and liver cancers when measures to prevent, diagnose, and treat liver disease and liver cancer are available.
As part of its Liver Health is Public Health initiative, Global Liver Institute’s (GLI) recent Global State of Liver Health report has exposed alarming trends in liver disease through compiled statistics and expert perspectives.
As members of Global Liver Institute’s Liver Action Network (LAN), the undersigned organizations are proud to take part in World Obesity Day. We recognize the relationship between nonalcoholic fatty liver disease (NAFLD), its advanced form, nonalcoholic steatohepatitis (NASH), and obesity.
(Washington D.C., February 1, 2023) – Global Liver Institute (GLI) launches its third annual #RareAware campaign today to raise awareness of and build resources for liver health challenges to maternal and neonatal well-being through a series of webinars, storytimes, and social media outreach. Liver diseases such as (spell out) ICP and BA can complicate a pregnancy or endanger a newborn’s earliest days, in the worst cases threatening the lives of baby and mother alike.
In 2021, Global Liver Institute (GLI) launched the Liver Action Network (LAN) to better synchronize engagement across the liver advocacy community and to meet the needs of a rapidly growing cadre of liver health advocates. The LAN operates as a first-of-its-kind network that provides community member organizations a central structure for the formulation of collective health policy and programmatic solutions.
Global Liver Institute (GLI), the premier patient-led liver health nonprofit operating globally, announces the launch of its Global State of Liver Health report as part of its Liver Health is Public Health (LHPH) initiative. Through compiled statistics and expert perspectives, the report paints a preliminary picture of the key issues in liver health worldwide as well as the unique challenges faced by communities in specific regions before providing recommendations for the future.
